alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2021463EN.01001601.xml

| 16.11.2021 | EN | Official Journal of the European Union | C 463/16 |
| --- | --- | --- | --- |

16.11.2021

EN

Official Journal of the European Union

C 463/16

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 463/15)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holders of the authorisation | Authorisation number | Authorised use | Date of expiry
  of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2021) 7877 | 9 November 2021 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany; | REACH/21/7/0 | In a washing buffer to purify biological APIs (active pharmaceutical ingredients) during the production of Palivizumab and Moxetumomab pasudotox-tdfk | 4 January 2033 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies. |
| Boehringer Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Wien, Austria. | REACH/21/7/1 |

Reference of the decision (2)

Date of decision

Substance name

Holders of the authorisation

Authorisation number

Authorised use

Date of expiry

of review period

Reasons for the decision

C(2021) 7877

9 November 2021

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany;

REACH/21/7/0

In a washing buffer to purify biological APIs (active pharmaceutical ingredients) during the production of Palivizumab and Moxetumomab pasudotox-tdfk

4 January 2033

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies.

Boehringer Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Wien, Austria.

REACH/21/7/1

---

(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu)

---
# C_2021290EN.01000101.xml

| 20.7.2021 | EN | Official Journal of the European Union | C 290/1 |
| --- | --- | --- | --- |

20.7.2021

EN

Official Journal of the European Union

C 290/1

---

Non-opposition to a notified concentration

(Case M.10323 — KKR/LGP/CNG)

(Text with EEA relevance)

(2021/C 290/01)

On 13 July 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10323. EUR-Lex is the online access to European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10323. EUR-Lex is the online access to European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
#### NEUPERT et al., Respondents, v. BROOKER et al., Appellants.

(Supreme Court, General Term, Fifth Department.

January 18, 1894.)

Action by Anthony Neupert and John C. Lutz against Hurbert H. Brooker and James Downs.

No opinion. Order of the county judge of Niagara county appealed from affirmed, with 810 costs and disbursements, on the authority of Bank v. Wilson, 13 Hun, 232.
# C_2021193EN.01000601.xml

| 20.5.2021 | EN | Official Journal of the European Union | C 193/6 |
| --- | --- | --- | --- |

20.5.2021

EN

Official Journal of the European Union

C 193/6

---

Prior notification of a concentration

(Case M.10204 — Total Produce/Dole Food Company)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 193/05)

1.

This notification concerns the following undertakings:

| — | Total Produce plc (‘Total Produce’, Republic of Ireland) |
| --- | --- |

—

Total Produce plc (‘Total Produce’, Republic of Ireland)

| — | DFC Holdings LLC (‘DFC Holdings’, United States of America) |
| --- | --- |

—

DFC Holdings LLC (‘DFC Holdings’, United States of America)

Total Produce enters into a full merger within the meaning of Article 3(1)(a) of the Merger Regulation with DFC Holdings and its wholly owned subsidiary, Dole Food Company Inc (‘Dole Food Company’). DFC Holdings and Dole Food Company are together referred to as ‘Dole’).

2.

| — | for Total Produce: import and distribution of a wide range of fresh fruit and vegetables, including bananas and pineapples. Total Produce also operates banana ripening centres and is active worldwide, with a focus on Europe. |
| --- | --- |

—

for Total Produce: import and distribution of a wide range of fresh fruit and vegetables, including bananas and pineapples. Total Produce also operates banana ripening centres and is active worldwide, with a focus on Europe.

| — | for Dole: production, sales and distribution of fresh fruit and vegetables, including bananas and pineapples, in North America, Europe, Latin America, South Africa and Dubai, with a main focus on North America. |
| --- | --- |

—

for Dole: production, sales and distribution of fresh fruit and vegetables, including bananas and pineapples, in North America, Europe, Latin America, South Africa and Dubai, with a main focus on North America.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10204 —Total Produce/Dole Food Company

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email:COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Veterans Affairs

The Department of Veterans Affairs (VA) gives notice under Public Law 92-463 that a meeting of the Advisory Committee on Prosthetics and Special-Disabilities Programs (Committee) will be held Monday and Tuesday, May 8-9, 2000, at VA Headquarters, Room 930, 810 Vermont Avenue, NW, Washington, D.C. The May 8 session will convene at 8:00 a.m. and adjourn at 4 p.m. and the May 9 session will convene at 8:00 a.m. and adjourn at 12:00 noon. The purpose of the Committee is to advise the Department on its prosthetic programs designed to provide state-of-the-art prosthetics and the associated rehabilitation research, development, and evaluation of such technology. The Committee also advises the Department on special disability programs which are defined as any program administered by the Secretary to serve veterans with spinal cord injury, blindness or vision impairment, loss of or loss of use of extremities, deafness or hearing impairment, or other serious incapacities in terms of daily life functions.

On the morning of May 8, the Committee will receive briefings by the National Program Directors of the Special-Disabilities Programs regarding the status of their activities over the last seven months. In the afternoon, a GAO representative will give a briefing on the GAO Draft Report regarding VA Health Care: Better Data and Accountability Needed For Care for Disabled Veterans. On the morning of May 9, the Committee will review the final draft report on implementation of the Veterans' Health Care Eligibility Reform Act of 1996 as it pertains to the legislative requirement to maintain capacity to meet specialized needs of disabled veterans. The Committee will have the opportunity to ask questions and provide input to the final draft report.

The meeting is open to the public. For those wishing to attend, contact Kathy Pessagno, Veterans Health Administration (113), phone (202) 273-8512, Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, D.C. 20420, prior to May 5, 2000.

Dated: April 5, 2000.

Marvin Eason,

Committee Management Officer.

[FR Doc. 00-9858  Filed 4-19-00; 8:45 am]

BILLING CODE 8320-01-M
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5804 Introduced in House (IH)]

111th CONGRESS
  2d Session
                                H. R. 5804

                     To prohibit trade in billfish.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             July 21, 2010

Mr. Shadegg (for himself, Ms. Ros-Lehtinen, Ms. Wasserman Schultz, Mr. 
  Cao, and Mr. Mario Diaz-Balart of Florida) introduced the following 
bill; which was referred to the Committee on Natural Resources, and in 
addition to the Committees on Foreign Affairs and Ways and Means, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL

 
                     To prohibit trade in billfish.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Billfish Conservation Act of 2010''.

SEC. 2. STATEMENT OF CONSTITUTIONAL AUTHORITY.

    The Congress enacts this Act pursuant to clause 3 of section 8 of 
article I of the United States Constitution.

SEC. 3. PROHIBITION ON TRADE IN BILLFISH.

    (a) Prohibition.--No person shall offer for sale, sell, import, or 
export, or have custody, control, or possession of for purposes of 
offering for sale, selling, importing, or exporting, billfish or 
products containing billfish.
    (b) Penalty.--For purposes of section 308(a) of the Magnuson-
Stevens Fishery Conservation and Management Act (16 U.S.C. 1858(a)), a 
violation of this section shall be treated as an act prohibited by 
section 307 of that Act (16 U.S.C. 1857).
    (c)  Billfish Defined.--In this section the term ``billfish''--
            (1) means any fish of the species--
                    (A) Makaira nigricans (blue marlin);
                    (B) Kajikia audax (striped marlin);
                    (C) Istiompax indica (black marlin);
                    (D) Istiophorus platypterus (sailfish);
                    (E) Tetrapturus angustirostris (shortbill 
                spearfish);
                    (F) Kajikia albida (white marlin);
                    (G) Tetrapturus georgii (roundscale spearfish);
                    (H) Tetrapturus belone (Mediterranean spearfish); 
                and
                    (I) Tetrapturus pfluegeri (longbill spearfish); and
            (2) does not include the species Xiphias gladius 
        (swordfish).
                                 <all>
```
(August 17, 1987)

#### Monique Bental, Respondent, v New York State Division of Human Rights, Respondent, and El Al Israel Airlines, Appellant.

In a proceeding pursuant to Executive Law § 298 to review two determinations of the New York State Division of Human Rights (hereinafter the division), both dated June 19, 1984, dismissing the petitioner’s complaints of sex and age discrimination, respectively, on the ground of no probable cause, El A1 Israel Airlines appeals from an order of the Supreme Court, Queens County (Miller, J.), dated October 24, 1985, which granted the petition, annulled the determinations, and remitted the matters to the division "for further investigation and a hearing”.

Ordered that the order is reversed, on the law, without costs or disbursements, and the proceeding is dismissed.

The petitioner filed with the division complaints of sex and age discrimination in connection with her termination from employment with El A1 Israel Airlines (hereinafter El Al). El A1 claimed that the petitioner was discharged as a result of its then deteriorating financial situation and its need to substantially reduce costs and streamline operations. El A1 asserted that sex and age discrimination were not factors in its decision to terminate the petitioner’s employment.

After investigation and following a review of related information and evidence with the named parties, the division determined that there is no probable cause to believe that El *136Al had engaged in or was engaging in the unlawful discriminatory practices of which the petitioner complained. Accordingly, the division dismissed the complaints.

The petitioner then instituted this proceeding in this court. By order dated September 9, 1985, this court transferred the proceeding for disposition to the Supreme Court, Queens County *(see,*L 1985, ch 340, § 2). Thereafter, in the order appealed from, Special Term granted the petitioner’s application to the extent that the matters were remitted to the division for further investigation and a hearing.

On El Al’s appeal from that order we have examined the record and the contentions of the parties and conclude that the division’s determinations dismissing the complaints on the ground of no probable cause should be sustained. We find that the discretion accorded to the division in making its investigation was not abused in this case. The investigation of the complaints alleging age and sex discrimination was not so abbreviated and one-sided that it resulted in a record which did not afford a reasonable basis for an administrative determination. Finally, on the state of the record before the division, it cannot be said that its findings of no probable cause were unsupported by substantial evidence *(see, Matter of Tirino v Long Is. Jewish-Hillside Med. Center,*99 AD2d 513). Thompson, J. P., Weinstein, Rubin and Spatt, JJ., concur. *[See,*130 Misc 2d 270.]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Office of the Secretary

# AGENCY:

Defense Intelligence Agency, Department of Defense.

# ACTION:

Notice.

# SUMMARY:

Pursuant to the provisions of subsection (d) of section 10 of Public Law 92-463, as amended by section 5 of Public Law 94-409, notice is hereby given that a closed meeting of the DIA Science and Technology Advisory Board has been scheduled as follows:

# DATES:

April 25, 2000 (8 a.m. to 4 p.m.).

# ADDRESSES:

The Defense Intelligence Agency, 200 MacDill Blvd., Washington, DC 20340.

# FOR FURTHER INFORMATION CONTACT:

Maj. Donald R. Culp, Jr., USAF, Executive Secretary, DIA Science and Technology Advisory Board, Washington, DC 20340-1328 (202) 231-4930.

# SUPPLEMENTARY INFORMATION:

The entire meeting is devoted to the discussion of classified information as defined in section 552b(c)(1), Title 5 of the U.S. Code, and therefore will be closed to the public. The Board will receive briefings on and discuss several current critical intelligence issues and advise the Director, DIA, on related scientific and technical matters.

Dated: April 12, 2000.

Patricia L. Toppings,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 00-9567 Filed 4-17-00; 8:45 am]

BILLING CODE 5001-10-M
Exhibit 13.1

GPC Biotech AG

Certification Pursuant to 18 U.S.C. Section 1350 as Enacted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

GPC
Biotech AG (the Company) is filing with the U.S. Securities and Exchange Commission, on the date hereof, its annual report on Form 20-F for the fiscal year ended December 31, 2006 (the Report). Pursuant to 18 U.S.C.
Section 1350 as enacted pursuant to the requirements of Section 906 of the Sarbanes-Oxley Act of 2002, I, Bernd R. Seizinger, the Chief Executive Officer of the Company, hereby certify that:

To the best of my knowledge:



| | (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | the information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------

Date: June 21, 2007



|                        |  | 
|----------------------- |  | 
|/s/ Bernd R. Seizinger  |  | 
|Bernd R. Seizinger      |  | 
|Chief Executive Officer |  | 

A signed original of this written statement required by Section 906 has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
SIXTH DISTRICT COURT OF APPEAL

STATE OF FLORIDA

_____________________________

Case No. 6D2024-0210

Lower Tribunal No. 22-CC-005506

_____________________________

XIAOSHENG YUE and JINSONG ZHANG,

Appellants,

v.

SAFE HARBOR TITLE COMPANY and MARISENA PENELOPE PEPPER,

Appellees.

_____________________________

Appeal from the County Court for Lee County.

Lindsay S. Garza, Judge.

July 12, 2024

PER CURIAM.

AFFIRMED. See Fla. R. App. P. 9.315(a).

STARGEL, WHITE and MIZE, JJ., concur.

Xiaosheng Yue and Jinsong Zhang, Kissimmee, pro se.

Stuart M. Pepper, Cape Coral, for Appellee, Marisena Penelope Pepper. 

No Appearance for Appellee, Safe Harbor Title Company. 

NOT FINAL UNTIL TIME EXPIRES TO FILE MOTION FOR REHEARING 

AND DISPOSITION THEREOF IF FILED
EXHIBIT
      32.2





CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES–OXLEY ACT OF 2002





I,
      George
      E. Strickler, Executive Vice President, Chief Financial Officer and Treasurer,
      of Stoneridge, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section
      1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      that:





(1)
      the
      report on Form 10-Q of the Company for the third quarter ended September 30,
      2008 (“the Report”) which this certification accompanies fully complies with the
      requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934
      (15 U.S.C. 78m(a) or 78o(d)); and





(2)
      the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.





/s/
                George E. StricklerGeorge
                E. Strickler, Executive Vice President, Chief Financial Officer and
                TreasurerNovember
                7, 2008





A
      signed
      original of this written statement required by Section 906 of the Sarbanes-Oxley
      Act of 2002 has been provided to the Company and will be retained by the Company
      and furnished to the Securities and Exchange Commission or its staff upon
      request.
#### In re GALPIN.

(Supreme Court, Appellate Division, Second Department.

October 18, 1896.)

Application by Henry F. Galpin for admission as attorney and counselor at law.

No opinion. Application granted, and the applicant may take the oath of office.
Exhibit 10.3

Promissory Note


$2595.00                                                      June 14, 2002
                                                          Newport Beach, CA


     On Demand for value received the undersigned promises to pay in lawful
money of the United States of America to the order of Mezzanine Fund
Management, Ltd., nominee or assignee, the sum of Two Thousand Five Hundred
Ninety Five Dollars ($2595.00), with interest from June 14, 2002 until paid
at the rate of ten percent (10%) per annum).

     Should interest not be paid, it shall thereafter bear interest as the
principal, but such unpaid interest so compounded shall not exceed an
amount equal to simple interest on the principal at the maximum rate
permitted by law.  The undersigned hereby waives presentment of payment,
protest, notice of protest, notice of nonpayment, and diligence in bringing
suit, and further agrees, in case suit is instituted, to collect this
Promissory Note or any portion thereof, to pay such additional sum for
attorneys' fees as the Court may adjudge reasonable in such suit.



                                   Whitelight Corporation



                                   By: /s/ Eric Chess Bronk
                                   ___________________________________
                                   Eric Chess Bronk, President